Chemocentryx, Inc.

Metabolex, Inc.

Cymabay Therapeutics, Inc.

Aaron Robert Novack

Jiangao Song

Xin Chen

Jingyuan Ma

Cheng Hu

Imad Nashashibi

Anita Melikian

William L Thomas

Sreenivas Punna

Andrew M K Pennell

Solomon Ungashe

Trevor T Charvat

Edward J Sullivan

Phuongly Pham

Christopher J Rabbat

Dong Fang Shi

Penglie Zhang

Jay Patrick Powers

Yibin Zeng

Xuefei Tan

Yan Zhu

Peng Cheng

Alison Murphy

Dong-Fang Shi

David W G Wone

Jeffrey D Johnson

Antoni Krasinski

Charles A McWherter

John Jessen Wright

Xueyan Wang

Brian Edward Lavan

The present disclosure relates to compounds that act as agonists of, or otherwise modulate the activity of, GPR131 and to their use in the treatment of various diseases. In particular embodiments, the structure of the compounds is given by Formula I: wherein the variables are as described herein. Related compositions, formulations and methods for the preparation of compounds of formula I are also described.

Bicyclic agonists of GPR131 and uses thereof

Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

N-(2-(hetaryl)aryl)arylsulfonamides and N-(2-(hetaryl)hetaryl)arylsulfonamides

Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control.

N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders

N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides

Chemical compounds which act as agonists of, or otherwise modulate the activity of, GPR131 are disclosed. Related compositions, formulations and methods of use are also described.

Agonists of GPR131 and uses thereof

GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

GPR120 receptor agonists and uses thereof

Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

Triazolyl phenyl benzenesulfonamides

N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl)hetaryl arylsulfonamides

N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides

Growing community of inventors

San Jose, CA, United States of America

Aaron Robert Novack